盤前時段
|
||||
|
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
0.78/-1.41
|
企業價值
3.30B
|
資產負債 |
每股賬面淨值
11.12
|
現金流量 |
現金流量率
0.10
|
損益表 |
收益
60.00M
|
每股收益
--
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Itspipeline products include Rusfertide (PTG-300) and JNJ-2113. |